2010 Annual Scientific Meeting and Exposition 2010 Annual ...

General InformationThis program book has been underwritten by Novartis PharmaceuticalsCorporation.EducationProgram ObjectivesIn keeping with the purpose of the American Society of Hypertension,Inc. (ASH), the Twenty-Fifth Annual Scientific Meeting is designed toencourage and promote the development, advancement, and exchangeof fair and balanced and evidence-based information regarding theresearch, diagnosis and treatment of hypertension and related cardiovasculardiseases, with the goal of improved patient care and health.The sessions will:• Present and examine new findings on the physiology, pathophysiology,epidemiology, diagnosis, and management of hypertensionand related conditions.• Review current state-of-the-art advances in managing particulargroups of patients.• Evaluate specific treatment modalities and pharmacologicalagents.The Society has asked each Scientific Session Presenter to include alearning objective at the beginning of their presentation.Target AudiencePhysicians, scientists, pharmacists, physician assistants, nurses andother health care professionals with an interest in the mechanisms ormanagement of hypertension and related diseases will benefit fromattending Scientific Sessions, Satellite Symposia, Meet-the-ExpertSessions, Case Discussions, Poster Sessions and the ScientificExposition.Continuing Education CreditThe American Society of Hypertension, Inc. is accredited by theAccreditation Council for Continuing Medical Education to providecontinuing medical education for physicians. The American Society ofHypertension, Inc. designates this educational activity for a maximumof 32 AMA PRA Category 1 Credits. Each physician should claimcredit commensurate with the extent of their participation in theactivity.Conflict of Interest DisclosureThe American Society of Hypertension, Inc. strives to ensure balance,independence, objectivity, and scientific rigor in all of its educationalprograms. All faculty members participating in this program havebeen required to disclose any real or apparent conflict(s) of interestthat may have a direct bearing on the subject matter of the session inwhich they are participating. This includes relationships in place atthe time of the meeting or in the twelve (12) months preceding themeeting, with pharmaceutical companies, biomedical device manufacturers,or other corporations whose products or services are relatedto the subject matter of the presentation topic.The intent of the policy is to identify openly any conflict of interest sothat the listeners may form their own judgments about the presentationswith the full disclosure of the facts. All Conflict of Interest DisclosureStatements are available to meeting attendees in the program19